i'd say we had alot of feedback from our medical cannabis which we prescribed through the SAS-B scheme, im sure they would gained a lot of data bout the side effects of the product,
plus the difference is the amount of people we are testing, i think CAN tested 12 people where as we are testing 196 people. who knows, very exciting though
- Forums
- ASX - By Stock
- BOD
- Ann: Phase IIB Clinical Trial of Schedule 3
Ann: Phase IIB Clinical Trial of Schedule 3, page-10
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOD (ASX) to my watchlist
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BOD (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online